Drug Profile
Research programme: Filovirus immunotherapeutics - Inovio Pharmaceuticals
Alternative Names: dMAb - Inovio; INO 4200; Protein based therapeutic monoclonal antibody - Inovio; VGX 4200Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Inovio Pharmaceuticals
- Class DNA vaccines; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Ebola virus infections
Highest Development Phases
- No development reported Ebola virus infections; Marburg virus disease
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Marburg virus disease(Prevention) in USA (Intradermal)
- 08 Apr 2015 Preclinical trials in Ebola virus infections in USA (Parenteral)